Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by enhancing antitumor immune responses, including agents targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand (PD-L1). Here, PDCD1 is linked to cancer.